论文部分内容阅读
重组基因工程干扰素α－２ｂ治疗慢性乙型病毒性肝炎，总剂量３×１０６ＩＵ×４５针组：ＨＢｅＡｇ与ＨＢＶ－ＤＮＡ的近期阴转率为７０．８３％与７５．００％，１年阴转率为６２．５０％，抗ＨＢｅ１年阳转率为５８．３０％，与对照组相比有极显著差异（Ｐ＜０，００１）。１×１０６ＩＵ×６０针组：ＨＢｅＡｇ与ＨＢＶ－ＤＮＡ近期阴转率虽亦达５０．００％与４０．００％，但３个月后即降至１０．００％，抗ＨＢｅ１年阳转率仅１０．００％，与对照组相比无显著差异。本品对肝炎后肝硬化伴肝炎活动组患者亦具抑制病毒复制、控制肝炎活动及改善临床症状的疗效。本品的副作用发生率高，但均呈一过性，一般能耐受。
Recombinant genetically engineered interferon α-2b treatment of chronic hepatitis B, the total dose of 3 × 106IU × 45 needle group: the recent negative conversion rate of HBeAg and HBV-DNA was 70.83% and 75.00%, 1 year The transfer rate was 62.50%, anti-HBe1 annual conversion rate was 58.30%, compared with the control group were significantly different (P <0,001). 1 × 106IU × 60-pin group: Although the recent negative conversion rates of HBeAg and HBV-DNA reached 50.00% and 40.00%, they dropped to 10.00% after 3 months, 10.00%, no significant difference compared with the control group. The product of hepatitis cirrhosis with hepatitis activity group patients also inhibit viral replication, hepatitis control activities and improve clinical efficacy. The high incidence of side effects of this product, but were transient, generally able to tolerate.